2028 Clinical Development Pharmaceuticals Small Molecule 
The Pharma Data
JANUARY 19, 2021
TC-210 is currently in a Phase I/II trial for mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Syros Pharmaceuticals – Syros announced its IPO on January 20, offering 5.4 Ortho Clinical Diagnostics is a leader in in vitro diagnostics.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS. In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval.
Expert insights. Personalized for you.
52 
Let's personalize your content